Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
EDQM
0
USP
0
JP
0
Others
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers


1. Ibi362
2. Ly3305677
1. Ibi362
2. Glxc-26803
3. 2259884-03-0
| Molecular Weight | 4476 g/mol |
|---|---|
| Molecular Formula | C207H317N45O65 |
| XLogP3 | -12.6 |
| Hydrogen Bond Donor Count | 58 |
| Hydrogen Bond Acceptor Count | 70 |
| Rotatable Bond Count | 164 |
| Exact Mass | g/mol |
| Monoisotopic Mass | g/mol |
| Topological Polar Surface Area | 1750 |
| Heavy Atom Count | 317 |
| Formal Charge | 0 |
| Complexity | 10500 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 31 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Fujian Genohope Biotech is a leading provider of high-potency peptide APIs, offering GMP quality and worldwide delivery.
Guizhou Utide Biotechnology Co., Ltd. - Specialized GMP manufacturing for next-generation GLP-1 peptide APIs.

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Fujian Genohope Biotech is a leading provider of high-potency peptide APIs, offering GMP quality and worldwide delivery.
About the Company : Fujian Genohope Biotech Ltd, established in 2019, specializes in high-potency polypeptide APIs and provides global API and preparation manufacturing services. Co-founded by New Hop...
About the Company : ApiSyn Healthcare, established in 2017, is a vertically integrated manufacturer of APIs & intermediates serving the global pharmaceutical industry. As part of SynZeal Research, a p...
Guizhou Utide Biotechnology Co., Ltd. - Specialized GMP manufacturing for next-generation GLP-1 peptide APIs.
About the Company : Guizhou Utide Biotechnology Co., Ltd., based in Zunyi, Guizhou, is a specialized manufacturer of GLP-1 peptide APIs with 20,000 m² of manufacturing facilities. Backed by a core te...
About the Company : Shenzhen JYMed Technology Co.,Ltd is a high-tech enterprise engaged in research and development, manufacturing and commercialization of peptides based products, including active ph...

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Partnership expands across oncology and immunology, strengthening Lilly’s next-generation pipeline. Innovent will lead programs from discovery through Phase II trials in China; Lilly gains exclusive rights outside Greater China.
Lead Product(s): Mazdutide,Inapplicable
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: DiscoveryProduct Type: Antibody, Unconjugated
Sponsor: Eli Lilly
Deal Size: $8,850.0 million Upfront Cash: $350.0 million
Deal Type: Collaboration February 09, 2026

Lilly, Innovent Ink $8.8B Collaboration Beyond Licensing
Details : Partnership expands across oncology and immunology, strengthening Lilly’s next-generation pipeline. Innovent will lead programs from discovery through Phase II trials in China; Lilly gains exclusive rights outside Greater China.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : $350.0 million
February 09, 2026

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Mazdutide is a peptide candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Obesity.
Lead Product(s): Mazdutide,Inapplicable
Therapeutic Area: Nutrition and Weight Loss Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Peptide, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 28, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Mazdutide,Inapplicable
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of IBI362 in Chinese Adolescents With Obesity or Overweight
Details : Mazdutide is a peptide candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Obesity.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
November 28, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
IBI362 (mazdutide) is a first-in-class dual glucagon (GCG)/glucagon-like peptide-1 (GLP-1) receptor agonist, approved for glycemic control in adults with type 2 diabetes (T2D).
Lead Product(s): Mazdutide,Inapplicable
Therapeutic Area: Endocrinology Brand Name: IBI362
Study Phase: Approved FDFProduct Type: Peptide, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 19, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Mazdutide,Inapplicable
Therapeutic Area : Endocrinology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Innovent’s Mazdutide Gains NMPA Approval in China for Type 2 Diabetes Glycemic Control
Details : IBI362 (mazdutide) is a first-in-class dual glucagon (GCG)/glucagon-like peptide-1 (GLP-1) receptor agonist, approved for glycemic control in adults with type 2 diabetes (T2D).
Product Name : IBI362
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
September 19, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
IBI-362 (mazdutide) is the world's first dual GCG/GLP-1 receptor agonist. It is being indicated for chronic weight management in Chinese adults with overweight or obesity.
Lead Product(s): Mazdutide,Inapplicable
Therapeutic Area: Nutrition and Weight Loss Brand Name: IBI-362
Study Phase: Approved FDFProduct Type: Peptide, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 26, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Mazdutide,Inapplicable
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Innovent’s Mazdutide Gets NMPA Nod As Dual GCG/GLP-1 For Weight Control
Details : IBI-362 (mazdutide) is the world's first dual GCG/GLP-1 receptor agonist. It is being indicated for chronic weight management in Chinese adults with overweight or obesity.
Product Name : IBI-362
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
June 26, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
IBI362 is a Peptide drug candidate, which is currently being evaluated in Phase I/ Phase II clinical studies for the treatment of Obesity.
Lead Product(s): Mazdutide,Inapplicable
Therapeutic Area: Nutrition and Weight Loss Brand Name: Undisclosed
Study Phase: Phase I/ Phase IIProduct Type: Peptide, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 03, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Mazdutide,Inapplicable
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Tolerance & Pharmacokinetics of IBI362 15mg in Moderate to Severe Obese Patients
Details : IBI362 is a Peptide drug candidate, which is currently being evaluated in Phase I/ Phase II clinical studies for the treatment of Obesity.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
June 03, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
IBI362 (mazdutide) is a glucagon-like peptide-1 receptor GLP-1R/GCGR dual agonist. It is being evaluated in patients with obesity accompanied fatty liver disease.
Lead Product(s): Mazdutide,Inapplicable
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Peptide, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 15, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Mazdutide,Inapplicable
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Mazdutide vs Semaglutide GLORY-3 Trial Begins First Dosing in China
Details : IBI362 (mazdutide) is a glucagon-like peptide-1 receptor GLP-1R/GCGR dual agonist. It is being evaluated in patients with obesity accompanied fatty liver disease.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
May 15, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
IBI362 is a Peptide drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Non-alcoholic Fatty Liver Disease.
Lead Product(s): Mazdutide,Inapplicable
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Peptide, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 22, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Mazdutide,Inapplicable
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of IBI362 in Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Details : IBI362 is a Peptide drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Non-alcoholic Fatty Liver Disease.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
April 22, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
IBI362 is a Peptide drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Sleep Apnea Syndromes.
Lead Product(s): Mazdutide,Inapplicable
Therapeutic Area: Sleep Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Peptide, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 16, 2025

A Study of IBI362 in Chinese Subjects With Obstructive Sleep Apnea and BMI≥28 kg/m2
Details : IBI362 is a Peptide drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Sleep Apnea Syndromes.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
April 16, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
IBI362 is a Peptide drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Overweight.
Lead Product(s): Mazdutide,Inapplicable
Therapeutic Area: Nutrition and Weight Loss Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Peptide, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 19, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Mazdutide,Inapplicable
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : IBI362 is a Peptide drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Overweight.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
March 19, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
IBI362 is a Peptide drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Obesity.
Lead Product(s): Mazdutide,Inapplicable
Therapeutic Area: Nutrition and Weight Loss Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Peptide, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 06, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Mazdutide,Inapplicable
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of IBI362 in Subjects With HFpEF or HFmrEF Combined With Obesity
Details : IBI362 is a Peptide drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Obesity.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
March 06, 2025

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]ABOUT THIS PAGE
93
PharmaCompass offers a list of Mazdutide API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Mazdutide manufacturer or Mazdutide supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Mazdutide manufacturer or Mazdutide supplier.
PharmaCompass also assists you with knowing the Mazdutide API Price utilized in the formulation of products. Mazdutide API Price is not always fixed or binding as the Mazdutide Price is obtained through a variety of data sources. The Mazdutide Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Mazdutide manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Mazdutide, including repackagers and relabelers. The FDA regulates Mazdutide manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Mazdutide API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Mazdutide manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Mazdutide supplier is an individual or a company that provides Mazdutide active pharmaceutical ingredient (API) or Mazdutide finished formulations upon request. The Mazdutide suppliers may include Mazdutide API manufacturers, exporters, distributors and traders.
click here to find a list of Mazdutide suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
Mazdutide Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Mazdutide GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Mazdutide GMP manufacturer or Mazdutide GMP API supplier for your needs.
A Mazdutide CoA (Certificate of Analysis) is a formal document that attests to Mazdutide's compliance with Mazdutide specifications and serves as a tool for batch-level quality control.
Mazdutide CoA mostly includes findings from lab analyses of a specific batch. For each Mazdutide CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Mazdutide may be tested according to a variety of international standards, such as European Pharmacopoeia (Mazdutide EP), Mazdutide JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Mazdutide USP).